SynthesisFrontiers in pharmacology2025
Effect of Chinese herbal medicine on sexual characteristics of females with precocious puberty: a meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Syndrome differentiation and treatment of pediatric central precocious puberty: role of the spleen-kidney axis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Precocious puberty (PP) in girls is a growing concern globally, characterized by the early onset of sexual characteristics. Chinese Herbal Medicine (CHM) has been proposed as a therapeutic intervention. This meta-analysis evaluates the effects of CHM on primary and secondary sexual characteristics in females with precocious puberty. Methods: A comprehensive literature search was conducted in Medline, Web of Science, Scopus, China National Knowledge Infrastructure Chinese Biomedical Literature Database (CBM), and Wan-fang database for clinical studies evaluating CHM in girls with precocious puberty. Key outcomes analyzed were primary and secondary sexual traits, including the uterine and ovarian volume and breast nucleus diameter. Data was pooled using a random-effects model and expressed as Standardized Mean Differences (SMD) with 95% confidence intervals. Results: Twenty-five studies involving 2096 patients were included. CHM significantly decreased breast nucleus diameter (SMD = -1.48, 95% CI [-2.04, -0.92]), reduced uterine volume (SMD = -0.75, 95% CI [-1.24, -0.27]), ovarian volume (SMD = -0.63, 95% CI [-0.97, -0.30]), and follicular volume (SMD = -0.87, 95% CI [-1.49, -0.26]). Subgroup analysis showed the integration of CHM and GnRHa resulted in a notable decrease in the development of sexual traits when compared to GnRHa alone. There was no significant difference between CHM and GnRHa in treating sexual traits. Sensitivity analysis was conducted to address the source of heterogeneity. Conclusion: CHM appears to effectively modulate primary sexual characteristics in females with precocious puberty. The findings of this study suggest that CHM is a good choice for adjuvant therapy along with GnRHa and also may serve as a complementary treatment for patients with PP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.